 BETHLEHEM, Pa., Jan. 26, 2021 GLOBE NEWSWIRE -- OraSure Technologies, Inc. NASDAQ: OSUR, a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that Chronomics Limited has selected the OMNIgeneORAL OME-505 saliva collection device as a component of its SARS CoV-2 PCR test. Chronomics Limited will supply its test for the United Kingdoms Test to Release for International Travel program. The OMNIgeneORAL device is a product of OraSures DNA Genotek subsidiary. 